

10 October 2024

Dear Researcher,

The next Global Vaccine and Immunization Research Forum (GVIRF) will be held on 25-27 March 2025, in Rio de Janeiro, Republic of Brazil. GVIRF is sponsored by the Gates Foundation, the U.S. National Institute of Allergy and Infectious Diseases, and the World Health Organization (WHO). It brings together researchers from around the world to discuss advances in vaccine and immunization research and review progress towards achieving [Immunization Agenda 2030](#) objectives in Research and Innovation.

It is our pleasure to invite you to **submit a research abstract** for consideration for the GVIRF 2025 poster session. Topics can include any aspect of basic or applied vaccine and immunization research, but topics related to the session agenda are especially welcome (please see the attached draft agenda).

Accepted applicants will be notified by email by January 10, 2025. Preference will be given to early-career scientists from the region and representatives from vaccine manufacturers in developing countries. Presenting authors of accepted abstracts will be invited to prepare a poster. If your abstract is accepted, GVIRF will cover travel expenses, subject to WHO travel policies.

Submission Guidelines

- **Deadline:** November 22, 2024, at 11:59 PM EST (UTC-05:00).
- **Transmission:** Please email your abstract to GVIRFAbstracts@niaid.nih.gov. Please include the curriculum vitae (CV) of the presenting author in the submission.

Abstract Guidelines

- **Languages:** Please prepare your abstract and poster in English. GVIRF will be conducted primarily in English, with simultaneous translation into Portuguese and Spanish.
- **Title:** Please submit the title exactly as you wish it to be presented in the program (maximum 20 words). Ensure that the title effectively conveys the primary message of your study.
- **Authors:** Include all contributing authors in your abstract submission. Indicate which author will be presenting the poster.
- **Structure:** Abstracts should contain the following sections: Introduction, Methods, Results, and Conclusions.
- **Proofread:** Avoid using incomplete sentences and redundant phrases. Ensure thorough proofreading to eliminate any misspellings or grammatical errors.
- **Length:** 250 to 500 words.
- **Font:** Arial size 12.

Please share this call for abstracts with colleagues engaged in vaccine and immunization research.

If you have any questions, please contact GVIRFAbstracts@niaid.nih.gov.

Sincerely,

The Global Vaccine and Immunization Research Forum Secretariat